
Photo: Created with AI
Get the latest FDA updates on medication recalls, manufacturing violations, and quality concerns that could affect your prescriptions

Photo: Created with AI
Welcome to the FDA Recalls and Warnings Update, a series dedicated to keeping you informed about the latest medication recalls, manufacturing violations, and quality concerns affecting your prescriptions. In this installment, we cover recalls involving abiraterone, amitriptyline, cinacalcet, metoclopramide, compounded testosterone cypionate, and Ultimate Forza, along with an FDA warning about Ultra Bon dietary supplement. This installment also features a facility inspection warning letter addressed to Empower Clinic Services, a compounding pharmacy doing business as Empower Pharmacy.
Consumers may wish to check the linked enforcement report for the list of affected product lot numbers and expiration dates. For prescription drugs that don’t include a lot number on the packaging, consumers may check with their pharmacist to see whether a medication is affected by the recall.
The Food and Drug Administration (FDA) categorizes product recalls in its Enforcement Report database based on the level of health risk, labeling them as Class I, II, III, or “not yet classified.”
While the database includes drugs, food, cosmetics, medical devices, biologics, tobacco, and veterinary products, this report only covers selected drug recalls.
Drug manufacturers, supplement companies, and medical device makers may receive a Warning Letter from the FDA if they commit serious violations of federal regulations. This letter comes from an overseeing FDA office, such as the Center for Drug Evaluation and Research. Common violations include poor manufacturing practices, false product claims, selling misbranded items, or marketing unapproved products. The letter gives the recipient a chance to correct the issues and requires a response, usually within 15 days.
FDA Import Alerts notify field staff and the public when the agency has enough evidence to detain products without physical examination (DWPE) due to suspected violations of FDA laws, including violations of “current good manufacturing practices for finished pharmaceuticals” or unapproved new drugs. The violations lists are arranged by type of violation, then by country and then by the importing company. In some cases, Import Alerts may be linked to Warning Letters for issues like manufacturing violations.
Drug Purpose: Treats metastatic prostate cancer; to be used along with prednisone.
Company: Glenmark Pharmaceuticals Inc., USA
Manufacturing Location: Not specified; distributed by Glenmark Pharmaceuticals, Elmwood Park, New Jersey
Scope: 1,296 60-count bottles of 500 mg tablets
Recall Reason: An unspecified labeling issue
Recall Initiation Date: October 9, 2026
Recall Level: Class II
Link: FDA Enforcement Report
Drug Purpose: Tricyclic antidepressant; sometimes used off-label to treat migraines or nerve pain. Tricyclic antidepressants affect the balance of neurotransmitters such as serotonin in the brain.
Company: AvKARE
Manufacturing Location: Not specified; manufactured for AvKARE, Pulaski, Tennessee
Scope: 3,534 50-count cartons of 10 mg 5 X 10 unit-dose cards
Recall Reason: Failed dissolution specifications; the tablets may not dissolve as intended, potentially affecting drug release and effectiveness.
Recall Initiation Date: October 2, 2026
Recall Level: Class II
Link: FDA Enforcement Report
Drug Purpose: Treats hyperparathyroidism, a condition in which one or more of the parathyroid glands in the neck produce too much parathyroid hormone.
Company: Strides Pharma Inc.
Manufacturing Location: Puducherry, India by Strides Pharma Science Ltd.
Scope: 49,488 30-count bottles of 30 mg tablets
Recall Reason: Failed dissolution specifications; the tablets may not dissolve as intended, potentially affecting drug release and effectiveness.
Recall Initiation Date: October 7, 2026
Recall Level: Class II
Link: FDA Enforcement Report
Drug Purpose: Prescription acid reflux treatment for adults who do not respond to other medications; treats diabetic gastroparesis, a condition in which food moves slowly out of the stomach; also used to treat nausea.
Company: Safecor Health, LLC
Manufacturing Location: Manufactured for Teva Pharmaceuticals, Parsippany, New Jersey
Scope: One lot of 5 mg, 100-count bottles (quantity in a lot not specified) distributed nationwide in the United States
Recall Reason: Co-mingled tablets. There is a risk that a bottle may contain a different product or strength.
Recall Initiation Date: October 6, 2026
Recall Level: Class II
Link: FDA Enforcement Report
Drug Purpose: Maintenance treatment for people with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. This medication is administered twice daily with a standard jet nebulizer (with a facemask or mouthpiece).
Company: The Ritedose Corporation
Manufacturing Location: Columbia, South Carolina, by The Rightdose Corporation
Scope: 3,210 cartons containing 30 or 60 individually wrapped vials, 20mcg/2mL solution
Recall Reason: Failed impurities and degradation specifications; this could affect product shelf life and quality.
Recall Initiation Date: October 15, 2026
Recall Level: Class II
Link: FDA Enforcement Report
Drug Purpose: A testosterone replacement therapy for adult males with conditions associated with a deficiency or absence of testosterone.
Company: Right Value Drug Stores LLC
Manufacturing Location: Irving, Texas
Scope: 4,675 vials (5 mL vials of 200 mg/mL and 30 mL vials of 200 mg/mL), both labeled for office use only.
Recall Reason: Lack of sterility assurance.
Recall Initiation Date: October 9, 2026
Recall Level: Class II
Essential Extras: The FDA inspected Right Value Drug Stores LLC, a drug compounding facility in Irving, Texas, from August 24 to September 8, 2026. Following the inspection, the FDA issued a Form 483 identifying six areas of concern, including inadequate testing of hormone pellets, problems monitoring contamination in clean rooms, and failures to follow quality control procedures. In one instance, the company updated its manufacturing instructions to address black particles found in a testosterone product but did not apply the corrective measures to other affected products. Inspectors also found that the company had not adequately investigated increases in mold detected in manufacturing areas.
Link: FDA Enforcement Report
Product Purpose: Promoted and sold as a dietary supplement for male performance
Company: Tonight We Ride, LLC
Manufacturing Location: Product label indicates it was manufactured in the USA
Scope: Covers all lots of Ultimate Forza Multi-Capsule/Box and Ultimate Forza Single Packs distributed through certain independently owned and operated GNC franchise locations in the United States from 2017 to October 1, 2026. GNC corporate stores did not sell the products.
Recall Reason: GNC’s third-party product testing service identified undeclared sildenafil, tadalafil, and dapoxetine. Sildenafil and Tadalafil are active ingredients in FDA-approved prescription drugs Viagra and Cialis, used to treat erectile dysfunction. These ingredients may interact with nitrates found in some prescription drugs, such as nitroglycerin, and may lower blood pressure to dangerous levels. Dapoxetine is not approved in the U.S., and therefore its safety or efficacy has not been established. Chemically, dapoxetine belongs to a class of drugs used to treat depression known as selective serotonin reuptake inhibitors (SSRIs). SSRIs have been shown to increase the risk of suicidal thinking and behavior in children, adolescents, and young adults.
Recall Initiation Date: October 24, 2026
Recall Level: Not yet classified
Essential Extras: Dapoxetine is sold under the brand name “Priligy” in many countries as a treatment for premature ejaculation. For a time, it was an investigational drug in the U.S., but the FDA rejected its application for new drug approval in 2005.
Link: Ultimate Forza Press Release
Check the Press Release for product photo and more information.
Product Purpose: Promoted and sold as a supplement for arthritis, pain, and osteoporosis
Scope: Sold on various websites, including ebay.com, and possibly in some retail stores
Warning: The FDA advises consumers not to purchase or use Ultra Bon because laboratory analysis confirmed it contains diclofenac not listed on the product label. Diclofenac is a Nonsteroidal Anti-Inflammatory Drug (NSAID) and is often prescribed to treat arthritis-related pain and inflammation. Oral formulations of diclofenac have a boxed warning about the risk of serious heart problems, such as heart attack and stroke, and gastrointestinal effects, such as bleeding, ulcers, or life-threatening tears in the stomach or intestinal lining. Diclofenac can interact with other medications, especially other NSAID-containing products, and may significantly increase the risk of these serious side effects.
Warning Date: October 15, 2026
Link: Ultra Bon Press Release and Health Fraud Product Database for Pain and Arthritis Products
Check the Press Release for product photo and more information.
The FDA has also warned consumers about other supplements containing hidden drug ingredients, including:
Ort-Flx: Contains diclofenac, dexamethasone (a steroid medication), and methocarbamol (a muscle relaxant)
RX7 Articulaciones: Contains diclofenac and dexamethasone
Demograss Premier (contains phenolphthalein, a chemical that is not an active ingredient in any FDA-approved drug. Studies suggest it may increase the risk of cancer.)
Type: Compounding pharmacy (503A type, licensed to compound patient-specific prescriptions)
FDA Department issuing Warning: Center for Drug Evaluation and Research (CDER)
Warning Letter Date: September 18, 2026
Facility Location: Houston, Texas
Date(s) of Inspections: November 3, 2025 to November 14, 2025; Inspection report (FDA Form 483) sent November 14, 2025
Types of Products Made: Sterile and non-sterile compounded medications, including these compounded GLP-1 and vitamin combination formulations identified in the warning letter: Tirzepatide/Niacinamide and Semaglutide/Cyanocobalamin.
Warning:
Based on a review of production records collected during the inspection, the FDA determined that Empower Clinic Services is compounding drugs that are “ineligible” to be produced in a 503A pharmacy. The FDA found that compounded tirzepatide and semaglutide products, with added vitamins niacinamide and cyanocobalamin, were essentially copies of FDA-approved drugs, not patient-specific formulations based on valid prescriptions for individually identified patients. FDA-approved diabetes and weight loss treatments Mounjaro and Zepbound contain tirzepatide, and FDA-approved Ozempic and Wegovy contain semaglutide.
The second set of warnings identified serious deficiencies in production processes that put patients at risk. The FDA found that products intended or expected to be sterile were prepared, packed, or held under insanitary conditions. The FDA found that while some of Empower’s corrective actions seem adequate, it lacks supporting documentation. The FDA found discrepancies in recordkeeping for tests measuring microbial growth in media test vials.
The agency noted that producing “ineligible drugs” is not exempt from Current Good Manufacturing Practice (CGMP) requirements. CGMP requires quality oversight and controls over drug manufacturing, including the safety of raw materials, materials used in drug manufacturing, and finished drug products.
Essential Extras: Founded in 2009, Empower claims to be the largest compounding pharmacy in the U.S. In addition to its 503A compounding facility, the subject of this warning letter, Empower also operates a registered 503B compounding outsourcing facility in Houston. Empower’s website says the 503B facility has advanced quality systems designed for high-volume sterile production. This large facility, more than 210k square feet (the size of four football fields), was also inspected during the same time frame as the 503A compounding pharmacy in November 2025. It also received an FDA Form 483 inspection report on November 14, 2025, documenting manufacturing violations and cleaning and disinfecting concerns.
Link: FDA Warning Letter
Read the warning letter for a complete description of violations.
DISCLAIMER: MedShadow provides information and resources related to medications, their effects, and potential side effects. However, it is important to note that we are not a substitute for professional medical advice, diagnosis, or treatment. The content on our site is intended for educational and informational purposes only. Individuals dealing with medical conditions or symptoms should seek guidance from a licensed healthcare professional, such as a physician or pharmacist, who can provide personalized medical advice tailored to their specific circumstances.
While we strive to ensure the accuracy and reliability of the information presented on MedShadow, we cannot guarantee its completeness or suitability for any particular individual’s medical needs. Therefore, we strongly encourage users to consult with qualified healthcare professionals regarding any health-related concerns or decisions. By accessing and using MedShadow, you acknowledge and agree that the information provided on the site is not a substitute for professional medical advice and that you should always consult with a qualified healthcare provider for any medical concerns.
Help fund our fight for improved medication safety and transparency by supporting our independent journalism.
Give NowIndependent, science-based health journalism. Free every Friday. No pharma funding.
We seek to create a world where there are safer medications for all and where all people are fully informed about their medication benefits and side effects, using our explanatory and investigative journalism to both inform and stimulate public discussion to drive toward solutions.
MedShadow.org is dedicated to empowering people with our evidence-based journalism about the safest ways to take over-the-counter (OTC) and prescription (Rx) medications.
We also seek to stimulate public discussion about potential improvements to drug research, manufacturing and distribution processes. and also to encourage the improvement of processes to ensure that we are all better protected.
As a result, we encourage other nonprofit newsrooms, mission-aligned outlets, and advocacy organizations to republish our original content under the following conditions:
1. We Are Credited Fully and Clearly
You must include the byline and credit MedShadow.org as the original publisher. Please include a link to the original article at the top or bottom of the piece. Use the following attribution:
This article was originally published by MedShadow, a nonprofit foundation that focuses on the safest ways to take over-the-counter and prescription medications.
2. Our Content Isn’t Edited Without Permission
You may make small changes for clarity, such as adjusting headlines, subheadings, or transitions, but you may not change the core meaning, tone, or intent of the article. For substantive edits, email us at republish@medshadow.org for review and approval.
3. You Do Not Sell Or Use Our Content Commercially
Our work is free to share, but it may not be sold, monetized, or repurposed for commercial gain. You may not republish our articles behind a paywall or in publications whose primary purpose is advertising or product promotion. You may not place drug or supplement advertising adjacent to our story.
4. Photos, Graphics, and Multimedia Are Not Used Without Permission
Only the text of the article is available for republication. Images, graphics, and videos may not be reused without explicit written permission, unless they are clearly marked as Creative Commons licensed. Contact us if you’d like to request reuse of a visual asset.
If you’re unsure whether your intended use falls within these guidelines, or would like to discuss a formal syndication or licensing arrangement, please email: republish@medshadow.org
We want our journalism to reach as many people as possible, especially those making critical decisions about medications and health.
For website editors
Copy the article body, including its formatting and links, then paste it into your publishing system. Add the byline and required credit described in these guidelines.
<!-- wp:paragraph -->
<p>Welcome to the FDA Recalls and Warnings Update, a series dedicated to keeping you informed about the latest medication recalls, manufacturing violations, and quality concerns affecting your prescriptions. In this installment, we cover recalls involving abiraterone, amitriptyline, cinacalcet, metoclopramide, compounded testosterone cypionate, and Ultimate Forza, along with an FDA warning about Ultra Bon dietary supplement. This installment also features a facility inspection warning letter addressed to Empower Clinic Services, a compounding pharmacy doing business as Empower Pharmacy.</p>
<!-- /wp:paragraph -->
<!-- wp:paragraph -->
<p>Consumers may wish to check the linked enforcement report for the list of affected product lot numbers and expiration dates. For prescription drugs that don’t include a lot number on the packaging, consumers may check with their pharmacist to see whether a medication is affected by the recall.</p>
<!-- /wp:paragraph -->
<!-- wp:group {"layout":{"type":"constrained"}} -->
<div class="wp-block-group"><!-- wp:heading -->
<h2 class="wp-block-heading">How To Read This Report</h2>
<!-- /wp:heading -->
<!-- wp:accordion -->
<div role="group" class="wp-block-accordion"><!-- wp:accordion-item -->
<div class="wp-block-accordion-item"><!-- wp:accordion-heading -->
<h3 class="wp-block-accordion-heading has-icon has-icon-right"><button type="button" class="wp-block-accordion-heading__toggle"><span class="wp-block-accordion-heading__toggle-title">Recalls (Enforcement Reports Database)</span><span class="wp-block-accordion-heading__toggle-icon" aria-hidden="true">+</span></button></h3>
<!-- /wp:accordion-heading -->
<!-- wp:accordion-panel -->
<div role="region" class="wp-block-accordion-panel"><!-- wp:paragraph -->
<p>The Food and Drug Administration (FDA) categorizes product recalls in its Enforcement Report database based on the level of health risk, labeling them as Class I, II, III, or "not yet classified."</p>
<!-- /wp:paragraph -->
<!-- wp:paragraph -->
<p>While the database includes drugs, food, cosmetics, medical devices, biologics, tobacco, and veterinary products, this report only covers selected drug recalls.</p>
<!-- /wp:paragraph -->
<!-- wp:list -->
<ul class="wp-block-list"><!-- wp:list-item -->
<li>Class I recalls are the most serious. In these situations, there is "reasonable probability that the use of or exposure to a product will cause serious adverse health consequences or death."</li>
<!-- /wp:list-item -->
<!-- wp:list-item -->
<li>Class II recalls are for drugs that may cause temporary or medically reversible adverse health consequences or where use of the product is unlikely to result in serious adverse health consequences.</li>
<!-- /wp:list-item -->
<!-- wp:list-item -->
<li>Class III recalls are the least serious. Use of the product is not likely to cause adverse health consequences.</li>
<!-- /wp:list-item --></ul>
<!-- /wp:list --></div>
<!-- /wp:accordion-panel --></div>
<!-- /wp:accordion-item --></div>
<!-- /wp:accordion -->
<!-- wp:accordion -->
<div role="group" class="wp-block-accordion"><!-- wp:accordion-item -->
<div class="wp-block-accordion-item"><!-- wp:accordion-heading -->
<h3 class="wp-block-accordion-heading has-icon has-icon-right"><button type="button" class="wp-block-accordion-heading__toggle"><span class="wp-block-accordion-heading__toggle-title">Warning Letters (Warning Letters Database)</span><span class="wp-block-accordion-heading__toggle-icon" aria-hidden="true">+</span></button></h3>
<!-- /wp:accordion-heading -->
<!-- wp:accordion-panel -->
<div role="region" class="wp-block-accordion-panel"><!-- wp:paragraph -->
<p><br>Drug manufacturers, supplement companies, and medical device makers may receive a Warning Letter from the FDA if they commit serious violations of federal regulations. This letter comes from an overseeing FDA office, such as the Center for Drug Evaluation and Research. Common violations include poor manufacturing practices, false product claims, selling misbranded items, or marketing unapproved products. The letter gives the recipient a chance to correct the issues and requires a response, usually within 15 days.<br></p>
<!-- /wp:paragraph --></div>
<!-- /wp:accordion-panel --></div>
<!-- /wp:accordion-item --></div>
<!-- /wp:accordion -->
<!-- wp:accordion -->
<div role="group" class="wp-block-accordion"><!-- wp:accordion-item -->
<div class="wp-block-accordion-item"><!-- wp:accordion-heading -->
<h3 class="wp-block-accordion-heading has-icon has-icon-right"><button type="button" class="wp-block-accordion-heading__toggle"><span class="wp-block-accordion-heading__toggle-title">Drug Imports Alerts Database</span><span class="wp-block-accordion-heading__toggle-icon" aria-hidden="true">+</span></button></h3>
<!-- /wp:accordion-heading -->
<!-- wp:accordion-panel -->
<div role="region" class="wp-block-accordion-panel"><!-- wp:paragraph -->
<p>FDA Import Alerts notify field staff and the public when the agency has enough evidence to detain products without physical examination (DWPE) due to suspected violations of <a href="https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211">FDA laws</a>, including violations of “current good manufacturing practices for finished pharmaceuticals” or <a href="https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-99">unapproved new drugs</a>. The violations lists are arranged by type of violation, then by country and then by the importing company. In some cases, Import Alerts may be linked to Warning Letters for issues like manufacturing violations.</p>
<!-- /wp:paragraph --></div>
<!-- /wp:accordion-panel --></div>
<!-- /wp:accordion-item --></div>
<!-- /wp:accordion --></div>
<!-- /wp:group -->
<!-- wp:heading -->
<h2 class="wp-block-heading">Drug Recalls</h2>
<!-- /wp:heading -->
<!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading">Abiraterone Acetate Tablets (generic for Abirtega)</h3>
<!-- /wp:heading -->
<!-- wp:paragraph -->
<p><strong>Drug Purpose</strong>: Treats metastatic prostate cancer; to be used along with prednisone.<br><strong>Company</strong>: Glenmark Pharmaceuticals Inc., USA<br><strong>Manufacturing Location</strong>: Not specified; distributed by Glenmark Pharmaceuticals, Elmwood Park, New Jersey<br><strong>Scope</strong>: 1,296 60-count bottles of 500 mg tablets<br><strong>Recall Reason</strong>: An unspecified labeling issue<br><strong>Recall Initiation Date</strong>: October 9, 2026<br><strong>Recall Level</strong>: Class II<br><strong>Link</strong>: <a href="https://www.accessdata.fda.gov/scripts/ires/index.cfm?Event=100128">FDA Enforcement Report</a></p>
<!-- /wp:paragraph -->
<!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading">Amitriptyline Hydrochloride Tablets</h3>
<!-- /wp:heading -->
<!-- wp:paragraph -->
<p><strong>Drug Purpose</strong>: Tricyclic antidepressant; sometimes used off-label to treat migraines or nerve pain. <a href="https://medlineplus.gov/druginfo/meds/a682388.html">Tricyclic antidepressants</a> affect the balance of neurotransmitters such as serotonin in the brain. <br><strong>Company</strong>: AvKARE<br><strong>Manufacturing Location</strong>: Not specified; manufactured for AvKARE, Pulaski, Tennessee<br><strong>Scope</strong>: 3,534 50-count cartons of 10 mg 5 X 10 unit-dose cards<br><strong>Recall Reason</strong>: Failed dissolution specifications; the tablets may not dissolve as intended, potentially affecting drug release and effectiveness.<br><strong>Recall Initiation Date</strong>: October 2, 2026<br><strong>Recall Level</strong>: Class II<br><strong>Link</strong>: <a href="https://www.accessdata.fda.gov/scripts/ires/index.cfm?Event=100061">FDA Enforcement Report</a></p>
<!-- /wp:paragraph -->
<!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading">Cinacalcet Tablets (generic for Sensipar)</h3>
<!-- /wp:heading -->
<!-- wp:paragraph -->
<p><strong>Drug Purpose</strong>: Treats <a href="https://medlineplus.gov/ency/article/001215.htm">hyperparathyroidism</a>, a condition in which one or more of the parathyroid glands in the neck produce too much parathyroid hormone.<br><strong>Company</strong>: Strides Pharma Inc.<br><strong>Manufacturing Location</strong>: Puducherry, India by Strides Pharma Science Ltd.<br><strong>Scope</strong>: 49,488 30-count bottles of 30 mg tablets<br><strong>Recall Reason</strong>: Failed dissolution specifications; the tablets may not dissolve as intended, potentially affecting drug release and effectiveness.<br><strong>Recall Initiation Date</strong>: October 7, 2026<br><strong>Recall Level</strong>: Class II<br><strong>Link</strong>: <a href="https://www.accessdata.fda.gov/scripts/ires/index.cfm?Event=100087">FDA Enforcement Report</a></p>
<!-- /wp:paragraph -->
<!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading">Metoclopramide Tablets, 5 mg (generic for Reglan)</h3>
<!-- /wp:heading -->
<!-- wp:paragraph -->
<p><strong>Drug Purpose</strong>: Prescription acid reflux treatment for adults who do not respond to other medications; treats diabetic gastroparesis, a condition in which food moves slowly out of the stomach; also used to treat nausea.<br><strong>Company</strong>: Safecor Health, LLC<br><strong>Manufacturing Location</strong>: Manufactured for Teva Pharmaceuticals, Parsippany, New Jersey<br><strong>Scope</strong>: One lot of 5 mg, 100-count bottles (quantity in a lot not specified) distributed nationwide in the United States<br><strong>Recall Reason</strong>: Co-mingled tablets. There is a risk that a bottle may contain a different product or strength.<br><strong>Recall Initiation Date</strong>: October 6, 2026<br><strong>Recall Level</strong>: Class II<br><strong>Link</strong>: <a href="https://www.accessdata.fda.gov/scripts/ires/index.cfm?Event=100075">FDA Enforcement Report</a></p>
<!-- /wp:paragraph -->
<!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading">Formoterol Fumarate Inhalation Solution (generic for Perforomist)</h3>
<!-- /wp:heading -->
<!-- wp:paragraph -->
<p><strong>Drug Purpose</strong>: Maintenance treatment for people with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. This medication is administered twice daily with a standard jet nebulizer (with a facemask or mouthpiece).<br><strong>Company</strong>: The Ritedose Corporation<br><strong>Manufacturing Location</strong>: Columbia, South Carolina, by The Rightdose Corporation<br><strong>Scope</strong>: 3,210 cartons containing 30 or 60 individually wrapped vials, 20mcg/2mL solution<br><strong>Recall Reason</strong>: Failed impurities and degradation specifications; this could affect product shelf life and quality.<br><strong>Recall Initiation Date</strong>: October 15, 2026<br><strong>Recall Level</strong>: Class II<br><strong>Link</strong>: <a href="https://www.accessdata.fda.gov/scripts/ires/index.cfm?Event=100124">FDA Enforcement Report</a></p>
<!-- /wp:paragraph -->
<!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading">Testosterone Cypionate Injection, compounded for intramuscular use</h3>
<!-- /wp:heading -->
<!-- wp:paragraph -->
<p><strong>Drug Purpose</strong>: A testosterone replacement therapy for adult males with conditions associated with a deficiency or absence of testosterone.<br><strong>Company</strong>: Right Value Drug Stores LLC<br><strong>Manufacturing Location</strong>: Irving, Texas<br><strong>Scope</strong>: 4,675 vials (5 mL vials of 200 mg/mL and 30 mL vials of 200 mg/mL), both labeled for office use only.<br><strong>Recall Reason</strong>: Lack of sterility assurance.<br><strong>Recall Initiation Date</strong>: October 9, 2026<br><strong>Recall Level</strong>: Class II<br><strong>Essential Extras</strong>: The FDA inspected Right Value Drug Stores LLC, a drug compounding facility in Irving, Texas, from August 24 to September 8, 2026. Following the inspection, the FDA issued a <a href="https://www.fda.gov/media/195071/download">Form 483</a> identifying six areas of concern, including inadequate testing of hormone pellets, problems monitoring contamination in clean rooms, and failures to follow quality control procedures. In one instance, the company updated its manufacturing instructions to address black particles found in a testosterone product but did not apply the corrective measures to other affected products. Inspectors also found that the company had not adequately investigated increases in mold detected in manufacturing areas.<br><strong>Link</strong>: <a href="https://www.accessdata.fda.gov/scripts/ires/?Event=100109">FDA Enforcement Report</a></p>
<!-- /wp:paragraph -->
<!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading">Ultimate Forza</h3>
<!-- /wp:heading -->
<!-- wp:paragraph -->
<p><strong>Product Purpose</strong>: Promoted and sold as a dietary supplement for male performance <br><strong>Company</strong>: Tonight We Ride, LLC<br><strong>Manufacturing Location</strong>: Product label indicates it was manufactured in the USA<br><strong>Scope</strong>: Covers all lots of Ultimate Forza Multi-Capsule/Box and Ultimate Forza Single Packs distributed through certain independently owned and operated GNC franchise locations in the United States from 2017 to October 1, 2026. GNC corporate stores did not sell the products.<br><strong>Recall Reason</strong>: GNC's third-party product testing service identified undeclared sildenafil, tadalafil, and dapoxetine. Sildenafil and Tadalafil are active ingredients in FDA-approved prescription drugs Viagra and Cialis, used to treat erectile dysfunction. These ingredients may interact with nitrates found in some prescription drugs, such as nitroglycerin, and may lower blood pressure to dangerous levels. Dapoxetine is not approved in the U.S., and therefore its safety or efficacy has not been established. Chemically, dapoxetine belongs to a class of drugs used to treat depression known as selective serotonin reuptake inhibitors (<a href="https://www.merriam-webster.com/dictionary/ssri#medicalDictionary">SSRIs</a>). SSRIs have been shown to increase the risk of suicidal thinking and behavior in children, adolescents, and young adults.<br><strong>Recall Initiation Date</strong>: October 24, 2026<br><strong>Recall Level</strong>: Not yet classified<br><strong>Essential Extras</strong>: Dapoxetine is sold under the brand name “Priligy” in many countries as a treatment for premature ejaculation. For a time, it was an investigational drug in the U.S., but the FDA rejected its application for new drug approval in 2005.<br><strong>Link</strong>: <a href="https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/tonight-we-ride-llc-issues-voluntary-recall-ultimate-forza-male-supplement-due-presence-undeclared">Ultimate Forza Press Release</a><br>Check the Press Release for product photo and more information.</p>
<!-- /wp:paragraph -->
<!-- wp:heading -->
<h2 class="wp-block-heading">FDA Warns of Undeclared Drugs in Supplements</h2>
<!-- /wp:heading -->
<!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading">Ultra Bon</h3>
<!-- /wp:heading -->
<!-- wp:paragraph -->
<p><strong>Product Purpose</strong>: Promoted and sold as a supplement for arthritis, pain, and osteoporosis<br><strong>Scope</strong>: Sold on various websites, including ebay.com, and possibly in some retail stores <br><strong>Warning</strong>: The FDA advises consumers not to purchase or use Ultra Bon because laboratory analysis confirmed it contains diclofenac not listed on the product label. Diclofenac is a Nonsteroidal Anti-Inflammatory Drug (NSAID) and is often prescribed to treat arthritis-related pain and inflammation. Oral formulations of diclofenac have a boxed warning about the risk of serious heart problems, such as heart attack and stroke, and gastrointestinal effects, such as bleeding, ulcers, or life-threatening tears in the stomach or intestinal lining. Diclofenac can interact with other medications, especially other NSAID-containing products, and may significantly increase the risk of these serious side effects.<br><strong>Warning Date</strong>: October 15, 2026<br><strong>Link</strong>: <a href="https://www.fda.gov/drugs/medication-health-fraud-notifications/ultra-bon-may-be-harmful-due-hidden-ingredient">Ultra Bon Press Release</a> and <a href="https://www.fda.gov/drugs/medication-health-fraud-notifications/pain-and-arthritis-products-containing-hidden-ingredients">Health Fraud Product Database for Pain and Arthritis Products<br></a>Check the Press Release for product photo and more information.</p>
<!-- /wp:paragraph -->
<!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading">Other Supplements Flagged by the FDA</h3>
<!-- /wp:heading -->
<!-- wp:paragraph -->
<p>The FDA has also warned consumers about other supplements containing hidden drug ingredients, including:</p>
<!-- /wp:paragraph -->
<!-- wp:heading {"level":4} -->
<h4 class="wp-block-heading"><strong>Sold as pain and arthritis supplements:</strong></h4>
<!-- /wp:heading -->
<!-- wp:paragraph -->
<p><a href="https://www.fda.gov/drugs/medication-health-fraud-notifications/ort-flx-may-be-harmful-due-hidden-ingredients">Ort-Flx</a>: Contains diclofenac, dexamethasone (a steroid medication), and methocarbamol (a muscle relaxant)<br><a href="https://www.fda.gov/drugs/medication-health-fraud-notifications/rx7-articulaciones-may-be-harmful-due-hidden-ingredients">RX7 Articulaciones</a>: Contains diclofenac and dexamethasone</p>
<!-- /wp:paragraph -->
<!-- wp:heading {"level":4} -->
<h4 class="wp-block-heading"><strong>Sold as weight loss supplements:</strong></h4>
<!-- /wp:heading -->
<!-- wp:paragraph -->
<p><a href="https://www.fda.gov/drugs/medication-health-fraud-notifications/demograss-premier-may-be-harmful-due-hidden-ingredient">Demograss Premier</a> (contains phenolphthalein, a chemical that is not an active ingredient in any FDA-approved drug. Studies suggest it may increase the risk of cancer.)</p>
<!-- /wp:paragraph -->
<!-- wp:heading -->
<h2 class="wp-block-heading">FDA Warning Letters</h2>
<!-- /wp:heading -->
<!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading">Empower Clinic Services, LLC dba Empower Pharmacy</h3>
<!-- /wp:heading -->
<!-- wp:paragraph -->
<p><strong>Type</strong>: Compounding pharmacy (503A type, licensed to compound patient-specific prescriptions)<br><strong>FDA Department issuing Warning</strong>: Center for Drug Evaluation and Research (CDER)<br><strong>Warning Letter Date</strong>: September 18, 2026<br><strong>Facility Location</strong>: Houston, Texas<br><strong>Date(s) of Inspections</strong>: November 3, 2025 to November 14, 2025; Inspection report (<a href="https://www.fda.gov/media/190207/download">FDA Form 483</a>) sent November 14, 2025<br><strong>Types of Products Made</strong>: Sterile and non-sterile compounded medications, including these compounded GLP-1 and vitamin combination formulations identified in the warning letter: Tirzepatide/Niacinamide and Semaglutide/Cyanocobalamin.<br><strong>Warning</strong>: </p>
<!-- /wp:paragraph -->
<!-- wp:paragraph -->
<p>Based on a review of production records collected during the inspection, the FDA determined that Empower Clinic Services is compounding drugs that are “ineligible” to be produced in a 503A pharmacy. The FDA found that compounded tirzepatide and semaglutide products, with added vitamins niacinamide and cyanocobalamin, were essentially copies of FDA-approved drugs, not patient-specific formulations based on valid prescriptions for individually identified patients. FDA-approved diabetes and weight loss treatments Mounjaro and Zepbound contain tirzepatide, and FDA-approved Ozempic and Wegovy contain semaglutide.</p>
<!-- /wp:paragraph -->
<!-- wp:paragraph -->
<p>The second set of warnings identified serious deficiencies in production processes that put patients at risk. The FDA found that products intended or expected to be sterile were prepared, packed, or held under insanitary conditions. The FDA found that while some of Empower’s corrective actions seem adequate, it lacks supporting documentation. The FDA found discrepancies in recordkeeping for tests measuring microbial growth in media test vials. </p>
<!-- /wp:paragraph -->
<!-- wp:paragraph -->
<p>The agency noted that producing “ineligible drugs” is not exempt from Current Good Manufacturing Practice (CGMP) requirements. <a href="https://www.fda.gov/drugs/pharmaceutical-quality-resources/current-good-manufacturing-practice-cgmp-regulations">CGMP</a> requires quality oversight and controls over drug manufacturing, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. </p>
<!-- /wp:paragraph -->
<!-- wp:paragraph -->
<p><strong>Essential Extras</strong>: Founded in 2009, Empower claims to be the <a href="https://www.empowerpharmacy.com/compound-medication/empower-news/empower-compounding-pharmacy-success/">largest compounding pharmacy</a> in the U.S. In addition to its <a href="http://www.empowerpharmacy.com/about/technology-innovation/facilities/503a/">503A compounding facility</a>, the subject of this warning letter, Empower also operates a registered <a href="https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities">503B compounding outsourcing facility</a> in Houston. <a href="https://www.empowerpharmacy.com/about/technology-innovation/facilities/">Empower’s website</a> says the 503B facility has advanced quality systems designed for high-volume sterile production. This large facility, more than 210k square feet (the size of four football fields), was also inspected during the same time frame as the 503A compounding pharmacy in November 2025. It also received an <a href="https://www.fda.gov/media/190736/download">FDA Form 483</a> inspection report on November 14, 2025, documenting manufacturing violations and cleaning and disinfecting concerns.<br><strong>Link</strong>: <a href="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/empower-clinic-services-llc-dba-empower-pharmacy-738238-09182026">FDA Warning Letter<br></a>Read the warning letter for a complete description of violations.</p>
<!-- /wp:paragraph -->We think it’s invaluable — and hope you agree. Our work is made possible by donations from readers like you.
We think it’s invaluable — and hope you agree. Our journalism is made possible by donations from readers like you.
As a nonprofit, we don’t take a dime from pharmaceutical or supplement companies. That means we can report on the benefits, risks, and alternatives to prescription and over-the-counter drugs free from corporate pressure or influence.